Table of Content

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Disease Type
3.2. Snippet by Product Type
3.3. Snippet by Therapy
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing Research Activities
4.1.1.2. Growing Prevalence
4.1.2. Restraints
4.1.2.1. High Treatment Costs
4.1.3. Opportunity
4.1.4. Government Initiatives
4.1.5. Impact Analysis
5. Industry Analysis
5.1. Porter’s 5 Forces Analysis
5.2. Regulatory Analysis
5.3. Pricing Analysis
5.4. Patent Analysis
5.5. Epidemiology Analysis
5.6. Reimbursement Scenarios
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID-19
6.1.2. Scenario During COVID-19
6.1.3. Post COVID-19 or Future Scenario
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturers’ Strategic Initiatives
6.6. Conclusion
7. Russia-Ukraine War Analysis
8. Global Recession Analysis
9. Artificial Intelligence Impact Analysis
10. By Disease Type
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
10.1.2. Market Attractiveness Index, By Disease Type
10.2. Hemophilia A
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Hemophilia B
10.4. Others
11. By Product Type
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
11.1.2. Market Attractiveness Index, By Product Type
11.2. Recombinant Coagulation *
11.2.1. Introduction
11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
11.3. Factor Concentrates
11.4. Plasma-derived Coagulation
11.5. Other
12. By Therapy
12.1. Introduction
12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
12.1.2. Market Attractiveness Index, By Therapy
12.2. Replacement Therapy
12.2.1. Introduction
12.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
12.3. Gene Therapy
12.4. Immune Tolerance Induction Therapy
13. By Region
13.1. Introduction
13.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
13.1.2. Market Attractiveness Index, By Region
13.2. North America
13.2.1. Introduction
13.2.2. Key Region-Specific Dynamics
13.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
13.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
13.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
13.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
13.2.6.1. The U.S.
13.2.6.2. Canada
13.2.6.3. Mexico
13.3. Europe
13.3.1. Introduction
13.3.2. Key Region-Specific Dynamics
13.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
13.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
13.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
13.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
13.3.6.1. Germany
13.3.6.2. The U.K.
13.3.6.3. France
13.3.6.4. Italy
13.3.6.5. Spain
13.3.6.6. Rest of Europe
13.4. South America
13.4.1. Introduction
13.4.2. Key Region-Specific Dynamics
13.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
13.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
13.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
13.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
13.4.6.1. Brazil
13.4.6.2. Argentina
13.4.6.3. Rest of South America
13.5. Asia-Pacific
13.5.1. Introduction
13.5.2. Key Region-Specific Dynamics
13.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
13.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
13.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
13.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
13.5.6.1. China
13.5.6.2. India
13.5.6.3. Japan
13.5.6.4. Australia
13.5.6.5. Rest of Asia-Pacific
13.6. Middle East and Africa
13.6.1. Introduction
13.6.2. Key Region-Specific Dynamics
13.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
13.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
13.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy
14. Competitive Landscape
14.1. Competitive Scenario
14.2. Market Share Analysis
14.3. Mergers and Acquisitions Analysis
15. Company Profiles
15.1. Bayer AG
15.1.1. Company Overview
15.1.2. Product Portfolio and Description
15.1.3. Financial Overview
15.1.4. Key Developments
15.2. BioMarin Pharmaceutical, Inc.
15.3. CSL Behring
15.4. Kedrion S.p.A
15.5. Novo Nordisk
15.6. Pfizer, Inc.
15.7. Roche (Chugai Pharmaceutical Co.)
15.8. Sanofi (Genzyme Corporation)
15.9. Takeda Pharmaceutical (Shire Plc.)
15.10. Octapharma
LIST NOT EXHAUSTIVE
16. Appendix
16.1. About Us and Services
16.2. Contact Us